Stephan Grupp
MD, PhD
Section Chief, Bone Marrow Transplant
👥Biography 个人简介
Stephan Grupp led the pivotal trials that resulted in the first FDA approval of a CAR-T cell therapy, tisagenlecleucel, for pediatric and young adult relapsed/refractory B-cell ALL. His work on cytokine release syndrome pathophysiology and the use of tocilizumab to manage severe CRS has defined modern supportive care for CAR-T therapy. He continues to lead research into next-generation CAR-T constructs for ALL.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 Stephan Grupp 的研究动态
Follow Stephan Grupp's research updates
留下邮箱，当我们发布与 Stephan Grupp（Children's Hospital of Philadelphia）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment